"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 12 | 10 | 22 |
| 1995 | 7 | 17 | 24 |
| 1996 | 4 | 11 | 15 |
| 1997 | 4 | 7 | 11 |
| 1998 | 6 | 16 | 22 |
| 1999 | 10 | 18 | 28 |
| 2000 | 7 | 12 | 19 |
| 2001 | 14 | 20 | 34 |
| 2002 | 11 | 15 | 26 |
| 2003 | 15 | 15 | 30 |
| 2004 | 23 | 16 | 39 |
| 2005 | 25 | 20 | 45 |
| 2006 | 25 | 15 | 40 |
| 2007 | 30 | 13 | 43 |
| 2008 | 23 | 21 | 44 |
| 2009 | 31 | 19 | 50 |
| 2010 | 40 | 24 | 64 |
| 2011 | 19 | 13 | 32 |
| 2012 | 17 | 11 | 28 |
| 2013 | 18 | 9 | 27 |
| 2014 | 18 | 13 | 31 |
| 2015 | 13 | 7 | 20 |
| 2016 | 16 | 6 | 22 |
| 2017 | 27 | 11 | 38 |
| 2018 | 23 | 14 | 37 |
| 2019 | 20 | 10 | 30 |
| 2020 | 14 | 12 | 26 |
| 2021 | 10 | 18 | 28 |
| 2022 | 4 | 19 | 23 |
| 2023 | 2 | 9 | 11 |
| 2024 | 11 | 4 | 15 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
-
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. N Engl J Med. 2024 Sep 26; 391(12):1119-1129.
-
Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication. Oncologist. 2024 Sep 06; 29(9):806-810.
-
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma. Lung Cancer. 2024 Sep; 195:107928.
-
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood Cancer J. 2024 07 08; 14(1):107.
-
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Mol Cancer. 2024 May 30; 23(1):115.
-
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
-
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY). Gastroenterology. 2024 Oct; 167(5):919-933.
-
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. Blood Cancer J. 2024 04 22; 14(1):69.
-
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN. Am J Hematol. 2024 07; 99(7):1257-1268.